Effectiveness of intensive smoking reduction counselling plus combination nicotine replacement therapy in promoting long-term abstinence in patients with chronic obstructive pulmonary disease not ready to quit smoking: Protocol of the REDUQ trial
- PMID: 29696216
- PMCID: PMC5898473
- DOI: 10.1016/j.conctc.2017.08.014
Effectiveness of intensive smoking reduction counselling plus combination nicotine replacement therapy in promoting long-term abstinence in patients with chronic obstructive pulmonary disease not ready to quit smoking: Protocol of the REDUQ trial
Abstract
Introduction: Limited tobacco dependence treatment resources exist for smoking COPD patients not ready to quit. Smoking reduction may be a viable treatment approach if it prompts quit attempts and subsequent abstinence. This article describes the protocol of the REDUQ (REDUce and Quit) study, which examines whether smoking reduction counselling plus combination nicotine replacement therapy (NRT) is (cost-)effective in achieving long-term abstinence in smoking COPD patients not ready to quit.
Methods/design: We conducted a two-centre, parallel-group, randomised controlled trial with 18 months follow-up in smoking outpatients with COPD. Patients not ready to quit within the next month but willing to reduce their smoking, were randomised to receive either intensive smoking reduction counselling plus combination NRT or a single information meeting plus self-help manual. Outcomes were assessed at baseline, 6, 12 and 18 months. The primary outcome is ≥ 1-year prolonged abstinence. Secondary outcomes are point prevalence abstinence, successful (i.e. ≥ 50%) smoking reduction, and incidence of quit attempts reported at follow-up assessments. Smoking status is biochemically verified by salivary cotinine and expired CO. Other variables include smoking-related cognitions, intention and motivation to reduce and quit smoking, withdrawal symptoms, health-related quality of life, symptoms of anxiety and depression, state of mindfulness, lung function, use of health care resources, and costs.
Discussion: The outcomes of the REDUQ trial will advance knowledge on treatment of smoking COPD patients not ready to quit. If (cost-)effective, the smoking reduction intervention can be offered to this difficult-to-treat target group as a valuable adjunct to smoking cessation treatment.
Keywords: Chronic obstructive pulmonary disease; Intervention; Nicotine replacement therapy; Randomised controlled trial; Smoking cessation; Smoking reduction.
Figures
References
-
- Global Initiative for Chronic Obstructive Lung Disease (GOLD) Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease - 2016. http://goldcopd.org/ Available from.
-
- Pauwels R.A., Rabe K.F. Burden and clinical features of chronic obstructive pulmonary disease (COPD) Lancet. 2004;364(9434):613–620. - PubMed
-
- Anthonisen N.R., Connett J.E., Kiley J.P., Altose M.D., Bailey W.C., Buist A.S.…O'Hara P. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. J. Am. Med. Assoc. 1994;272:1497–1505. - PubMed
-
- Fletcher C.M. Oxford University Press; New York: 1976. The Natural History of Chronic Bronchitis and Emphysema: an Eight Year Study of Early Chronic Obstructive Lung Disease in Working Men in London.
LinkOut - more resources
Full Text Sources
Other Literature Sources
